Sunday, 12 July 2020

Global Verrucous Carcinoma Market Trend, Industry Overview, Competitive Analysis And Foreseen By 2023

Market Insights
Verrucous Carcinoma typically debuts as an anomalous growth or as alteration in the constancy of an earlier potentially malignant ailment of the oral cavity. Verrucous Carcinoma is a rare, locally aggressive, clinically exophytic, low-grade, slow-growing, well-differentiated squamous cell carcinoma with nominal metastatic potential. It is unusual subtype of malignant ailment which affects oral cavity. Verrucous Carcinoma can affect all mucosal sites of the oral cavity. However, the frequency of malignant transformation of a leukoplakia to an OVC is considerably higher if they are in the gums in comparison to the tongue.
Verrucous Carcinoma is mainly caused by the snuffing of tobacco or chewing of tobacco. It is also referred to as snuff dipper's cancer. Verrucous Carcinoma mostly prevails at oral zones. The condition common in males within the age group 50 to 80 years. The increasing incidences of oral cancer primarily influences the market. Lifestyle factors such as smoking marijuana or tobacco and alcohol consumption mostly drives the Verrucous Carcinoma market. Additionally, growing consumption of alcohol, increasing adoption of sedentary lifestyle, increasing rates of sexually transmitted viruses by human papillomavirus, and family history of cancer prevalence contribute largely towards the development of the market. In 2015, the World Health Organization reported that 1.1 billion people smoked tobacco globally. This is likely to accelerate the market growth over the forecast period.
However, the high cost of surgical procedures, side effects associated with treatments, and expensive chemotherapy treatments are anticipated to limit the market growth to a certain extent.
Market Segmentation
The worldwide Verrucous Carcinoma market has been segmented based on treatment, end-user, and diagnosis.
Based on treatment, the Verrucous Carcinoma market has been segmented into radiation therapy, surgery, targeted drug therapy, and chemotherapy. Surgery has been sub-segmented into Mohs micrographic surgery and surgical excision. Chemotherapy has been sub-segmented into 5-fluorouracil, bleomycin, methotrexate, cisplatin, and others. Based on end-user, the Verrucous Carcinoma market has been segmented into ambulatory surgical centers, hospitals and clinics, research centers, diagnostic centers, and others. Based on diagnosis, the Verrucous Carcinoma market has been segmented into endoscopy, imaging tests, and biopsy. Imaging tests have been sub-segmented into magnetic resonance imaging, positron emission tomography scans, and computerized tomography scans.
Regional Analysis
The Americas represent the largest Verrucous Carcinoma market share in the global market. The market growth is owing to the increasing healthcare expenditure and surging prevalence of Human Papillomavirus (HPV). As recorded by the Genital HPV Infection, Fact Sheet 2017, 79 million American adults were infested with HPV. Europe (Belgium, UK, Netherlands, and France) represents the second largest Verrucous Carcinoma market over the forecast period. Rising prevalence of head and neck cancer drives the Verrucous Carcinoma market in this region. The Cancer Research UK revealed that in 2015, there were12061 new instances of neck and head cancer. These statistics substantially drive the Verrucous Carcinoma market in Europe.
In 2017, Asia-Pacific was estimated to be the fastest growing region for the worldwide Verrucous Carcinoma market. The market has been expected to develop owing to the rising addiction to smoking. According to the World Health Organization, in 2015, 33.7% and 47.6% of people smoked tobacco in Japan and China, respectively. The Middle East and Africa holds the least market share due to lack of availability of trained healthcare professionals and low per capita income in the region. Nevertheless, the growing palliative and oncology care services both at the community and the hospital level are expected to influence the market positively.
Key Players
The global Verrucous Carcinoma market is dominated by key players such as Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Bristol-Myers Squibb Company (US), Eli Lilly and Company. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Europe), Pfizer Inc. (US), Novartis AG (Europe), and others.
Posted by at No comments:

Global Hemorrhoids Treatment Market 2019 Analysis By Manufacturers, Latest Trends, Competitive Landscape And Strategies

Market Scenario:
The prevalence of hemorrhoids is found particularly between the age of 45 and 65, both in men and women. However, only a small percentage of the affected population seek any form of medical treatment like medication or surgery and instead opt for relief pills purchased from pharmacies.
Hemorrhoid is a highly uncomfortable disorder which is also known as piles. The condition is so subtle yet dangerous that most people under the age of fifty are unaware of the same. Hemorrhoids are inflamed, swollen veins situated in the anal canal and causes a strong sense of irritation in the form of both pain and itchiness. Patients who suffer from the same condition seek relief from a variety of products, boasting both negatives and positives. Direct products like wipes, creams, pads, and suppositories are highly effective at offering temporary period of relief. However, it is not effective enough for permanent treatments.
According to the latest report by the team of Market Research Future (MRFR), the global hemorrhoids treatment market size is expected to grow at a decent rate of 7.1% during the forecast period of 2018 to 2023. The market growth is influenced by numerous factors like the increasing prevalence of lifestyle-based diseases, growing demand for treatment, an increasing demand for reducing infections & complications relating to hemorrhoids, and an increasing number of surgeries. The growing old-age population is also one of the key contributors to the global demand for hemorrhoids treatment. However, lack of awareness and hesitancy towards medical treatment due to the feeling of embarrassment stands out as a key constraint to the growth of the global market.
Market Segmentation
The global hemorrhoids treatment market segmentation is based in terms of route of administration, treatment type, distribution channel, and region.
By treatment type, the market segments into drugs, surgical procedures, and non-surgical procedures. The drugs segment is further segmented into NSAIDs, laxatives, and herbals. The non-surgical procedures narrows down into cryotherapy, band litigation, and sclerotherapy.
By route of administration, the market divides into oral and topical agents.
By distribution channel, the market includes hospital pharmacies, retail pharmacies, online pharmacies, and others.
Regional Analysis
The regional segmentation of the global hemorrhoids market covers four major regions globally, namely Asia Pacific, Europe, the Americas, and the Middle East & Africa.
The Americas hold the maximum share of the market as per the global standings. The dominance of the region can be attributed to the huge patient population, high expenditure in the healthcare sector, and a well-established technology. The regional market for hemorrhoids treatment is expected to continue its dominance in the forthcoming years.
Europe accounts for the second largest market globally following the Americas. The European region is segmented into key regions, namely Western and Eastern Europe. The Western European region consists of countries like the UK, Germany, and France. Factors that primarily push the market in this region are the lack of any physical exercise, sedentary lifestyle, obesity, alcoholism, poor fiber intake in diet, etc.
Asia Pacific is slated to be the fastest growing regions in hemorrhoids. The growth in this region can be attributed to factors like the increasing demand for better diagnostic devices, rapidly improving technologies, better and safe therapeutic approach, and the presence of a massive talent pool.
Competitive Landscape
The global hemorrhoids treatment market holds a number of key players like Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company, Abbott Laboratories, Boston Scientific Corporation, GlaxoSmithKline, Pfizer Inc., AstraZeneca PLC, CONMED Corporation, Taro Pharmaceuticals Inc., Astra Zeneca, Olympus Corporation, Cook Medical, Glenmark Pharmaceuticals Bayer AG, Teva Pharmaceutical Industries Ltd, and others.
13th March 2019, Organization de Scalene announced recently the launch of Cryocure. Cryocure is an affordable medical device that is used to treat piles without any need for surgery.
8th April 2019, Trifecta Pharmaceuticals, one of the leading developers, distributors, and manufacturers of specialty OTC topical creams, gels, and ointments announced today about its distribution partnership with Walmart. The move will see Mayinglong, a hemorrhoid treatment ointment, being available on the shelves of the leading departmental store.
Posted by at No comments:

Worldwide Fibrocystic Breasts Diagnostics and Treatment Market Witness A Remarkable Growth Projected By 2023

More than half of women experience fibrocystic breast changes at some point in their lives. According to the American Cancer Society's evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.
The fibrocystic breast disease, also known as fibrocystic change or fibrocystic breasts, is a non-cancerous condition in which the breasts feel lumpy. The breast lumps are due to fibrocystic changes. These lumps are formed due to the collection of fibrous tissue at an area of the breast. The ligaments and scar tissues are made up of fibrous tissue. the changes in breast tissue due to the fluctuating hormone levels made by the ovaries results in the occurrence of fibrocystic breasts. The changes seem to be troublesome and result in breast swelling and painful breast lumps. It mainly affects women between their 30s and 50s and lingers through their perimenopause and menopause. Presence of fibrocystic breast disease increases the risk of breast cancer.
The global fibrocystic breasts diagnostics and treatment market is expected to register a significant growth during the forecast period (2018–2023).
Increase in incidences of breast cancer; especially among women above the age of 35 during menopause (are more susceptible to breast cancer), and growth in awareness regarding breast cancer screening programs drive the market growth. Additionally, the emergence of technologically advanced and minimally invasive breast biopsy devices is expected to provide lucrative opportunities in the untapped market.  However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Moreover, restrains for the market includes the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the global fibrocystic breasts diagnostics and treatment negatively. 
Key Players
Some of the key players in the global fibrocystic breast diagnostics and treatment market are Argon Medical Devices, Boston Scientific, CareFusion Corporation (Acquired by Becton, Dickinson and Company), C. R. Bard, Inc, Cook Medical, Devicor Medical Products Inc., Gallini Medical Devices, Hologic, Inc., INRAD, Inc., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd, Bayer AG, Allergan plc.
Regional Analysis
In the fibrocystic breast diagnostics and treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into cancer diagnostic. Whereas the market share in Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increasing government initiatives and rising healthcare expenditure.
The European market is expected to hold the second largest market share. The market growth in this region can be attributed to increasing amount of alcohol consumption by women, changes in estrogen levels due to increase in intake of birth control pills and increasing use of hormone replacement therapy (HRT) are boosting the European market.
The market in the Middle East & Africa is expected to account for the smallest share of the global fibrocystic breast diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Segmentation
The global fibrocystic breasts diagnostics and treatment market has been segmented into type and end users.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis is segmented into mammogram and breast biopsy. The treatment is segmented into medications, fine-needle aspiration, surgical excision, oral contraceptives. The medications are further segmented into acetaminophen, nonsteroidal anti-inflammatory drugs.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, rehab centers, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European fibrocystic breasts diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The fibrocystic breasts diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The fibrocystic breasts diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Posted by at No comments:

Distraction Osteogenesis Devices Market Innovative Treatments, Key Methodologies, Size, Growth, Top Players Success Milestones And Forecasts To 2023

Market Scenario:
Global Distraction Osteogenesis Devices Market Insights asserts, the market is expected to grow significantly over the forecast period. Distraction osteogenesis is the biological process of the new bone formation between bone segments which are gradually separated by incremental traction.  
Numerous factors such as advancements in distractor devices such as miniaturized internal and external devices, easily placeable and easy handling are expected to drive the growth of the market. For instance, In May 2018, DePuy Synthes, a part of the Johnson & Johnson Medical Devices Companies, announced an exclusive agreement in the US between DePuy Synthes Sales, Inc. and Prosidyan to promote the Fibergraft family of products, a line of synthetic bone graft materials which are ultra-porous, designed for ease of use, and have been engineered for ideal resorption in clinical use during spine fusion surgery. By adding Fibergraft to its offerings, DePuy Synthes will further enhance the company’s portfolio of biomaterials and distractors.
Moreover, various risks such as failure to follow the distraction protocol and damages to nerves hamper the market growth during the assessment period.
Key players
Johnson & Johnson Services, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, KLS Martin Group, Osteomed, Acumed LLC, Jeil Medical Corporation, Ningbo Cibei Medical Treatment Appliance Co., Ltd. Ortho Max Manufacturing Company Pvt. Ltd., Ortho Care and Titamed are some of the key players in the global distraction osteogenesis devices market.
Segmentation
The Global Distraction Osteogenesis Devices Market has been segmented into device type, age, application, and end-user.
The market, based on device type, has been segmented into mandibular distraction devices, palatal distraction devices, alveolar distraction devices, craniofacial distraction devices, Lefort distraction devices, small bone distraction devices, and others. The market, based on craniofacial distraction devices, has been further segmented into external and internal distractors. The market, based on external distractors is further classified into unidirectional distractors, bidirectional distractors, and multiplanar distractors whereas the market, based on, internal distractors can be classified into tooth-borne distractors, bone-borne distractors, and hybrid distractors. The market, by age, has been segmented into pediatrics and adults. The market, by application, has been segmented into dentistry, podiatry, orthopedics, and others. The market, by end-user, has been segmented into hospitals, orthopedic clinics, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Distraction Osteogenesis Devices Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European distraction osteogenesis devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Distraction Osteogenesis Devices Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The distraction osteogenesis devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Geographically, North America is expected to dominate the global distraction osteogenesis devices market owing to increasing number of procedures for treating facial abnormalities in the US. Also, most of the key players have their research and development teams working in this field in the US which in turn increases the awareness among the people about the technique in this region.
The European market is expected to be the second-largest due to increase in initiatives taken by public and private organizations in this field.
Posted by at No comments:

Wednesday, 8 July 2020

Cerebral Vasospasm Market Revenue, Opportunity, Forecast And Value Chain Analysis 2019

Global Cerebral Vasospasm Market - Scenario
The advances in medical knowledge are leading to the breakthroughs being achieved in the treatment of cerebral vasospasm. Reports that examine the medical device industry has been presented by Market Research Future, which produces reports on industry verticals that evaluate the market development and opportunities. The market is expected to gain a CAGR of 5.4 % in the upcoming period.
Cerebral vasospasm is most commonly observed in patients who survive subarachnoid hemorrhage. The narrowing of cerebral arteries is termed as cerebral vasospasm. Narrowing of cerebral artery leads to cerebral ischemia and then death. Increasing prevalence of subarachnoid hemorrhage and a rise in the prevalence of traumatic brain injury is the key factor driving the growth of the market.  According to the Centers for Disease Control and Prevention 2017, 30% of the total injury deaths are due to traumatic brain injury in the US. Other factors contributing to the growth of the market are increasing hypertension among the population, rising adoption of smoking, changing lifestyle, growing geriatric population, increasing prevalence of bleeding disorders, rising use of blood thinners and the introduction of technologically advanced treatments.
However, factors such as high cost associated with treatment, risks associated with drugs and medication and a shortage of skilled professionals are expected to hinder the market growth during the forecast period.
Segmentation
Global cerebral vasospasm market is segmented on the basis of type of treatment which includes triple-H therapy, nimodipine and other. On the basis of route of administration the market is segmented into oral, intravenous and intra-arterial and on the basis of end user the market is again segmented into hospitals, clinics and others.
Key Players
  • Headsense Medical Ltd (Israel),
  • Braun Melsungen AG (Germany),
  • Minnetronix, Inc (US),
  • Bristol-Myers Squibb Company (US),
  • Boehringer Ingelheim GmbH (Germany)  
  • Lundbeck A/S (Denmark)
Regional Analysis                                                                                
Geographically, North America has the largest market of cerebral vasospasm. North America cerebral vasospasm market is driven by robust research & development practices along with growing advancements in the field of neurology. Europe has the second largest market of cerebral vasospasm which is followed by Asia Pacific. In Middle East and Africa the market is least due to limited development in the healthcare sector. 
The report of global cerebral vasospasm market by Market Research Future comprises of extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts and key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the market’s different segments and regions.
Posted by at No comments:

Ventilator-Associated Pneumonia Market Segmentation Detailed Study With Forecast Up To 2019

Market Scenario
According to CDC in 2013, there were 2.8 million traumatic brain injury visits to emergency department and hospitals. The emergency department visits of brain injury patients increased by 47% from 2007. Thus, increasing incidence of TBI drives the growth of the market. Furthermore, increasing geriatric population is likely to fuel the market to grow.  According to the U.S. Census Bureau in 2015, 47.8 million people were 65 years or older, and in 2060, 98.2 million are expected to be 65 years or older.  Such increasing trend in the geriatric population provides favorable backgrounds for the market to grow.
Ventilator-associated pneumonia is a type of lung infection caused to patients who are on ventilators. Ventilator-associated pneumonia is caused mainly due to lung disease, neurologic disease, and trauma to critically ill persons. Diagnosing VAP requires aggressive surveillance combined with the radiographic examination, bedside examination, and microbiologic examinations of respiratory secretions. Growing Intensive Care Unit Admissions due to rising prevalence of respiratory diseases, rising number of ICU beds and high incidence of traumatic injuries provides favorable backgrounds for the market to grow.
However, factors such as expensive diagnostic tests, high ventilator charges, inappropriate reimbursement scenario, risks associated with ventilators are expected to restrict the market growth during the forecast period.
Key players
Some of the key players contributing in the global Ventilator-associated pneumonia market share  are Merck & Co., Inc. (U.S.), Adenium Biotech ApS (Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Austria) and other.
Segmentation
The global Ventilator-associated pneumonia market is segmented on the basis of diagnosis, mode of treatment, and end-user. The Ventilator-associated pneumonia market, by diagnosis categorized into Clinical Examination, Radiological Examination, Microbiological Analysis and others. Microbiological Analysis is further sub-segmented into Blood and pleural fluid cultures, Nonquantitative or semi-quantitative airway sampling and Quantitative cultures of airway specimens. Mode of treatment segment is segmented into Homecare, Hospital care, and others. On the basis of end-user, the market is segmented into Hospitals & Clinics, Research centers, Ambulatory Care Centers and Emergency Medical Services (EMS).      
Regional Market Summary
The Ventilator-associated pneumonia market is dominated by North America owing to the rising geriatric population within the region. The U.S. Census Bureau projected that in 2060, 19.7 million would be of age 85 or older. This influences the growth of this market in this region.
Asia Pacific was projected to be the fastest growing region for the global Ventilator-associated pneumonia market in 2017. The rising geriatric population, increasing healthcare expenditure and growing respiratory disorders in Asia is expected to drive market growth in this region. According to The Asian Development Bank (ADB), the geriatric population in Asia is estimated to reach 923 million by 2050. Thus, this provides favorable backgrounds for the Ventilator-associated pneumonia market to grow.
It is estimated that Europe stood second in the global Ventilator-associated pneumonia market owing to increasing prevalence of lung diseases. According to European respiratory society, more than 50% of deaths are due to lung diseases. Thus, increasing prevalence of lung diseases in this region influences the growth of this market in this region.
The Middle East and Africa holds the least share in the global Ventilator-associated pneumonia market due to the presence of stringent government policies, poor economies, under-developed healthcare infrastructure and low penetration of healthcare services, especially within the African region.
Posted by at No comments:

Dermal Fillers Market Dynamics, Forecast, Analysis And Supply Demand 2019

Dermal fillers or wrinkle fillers are solutions injected into the skin. Its effects can last from six months to two years. Efforts are being made to prolong its effects and revolutionize anti-aging. The global dermal filler market report by Market Research Future (MRFR) makes projections and estimates for the period of 2019 to 2025 (forecast period). It analyzes different segments and sub-segments and studies the penetration of these products at country levels.
Dermal Fillers Market Scope
The global dermal filler market can reach a valuation of USD 6,899.16 million by 2025. It is predicted to expand at a CAGR of 13.2% over the forecast period.
Major factors driving market growth include preference of non-invasive surgeries, economically affordable alternatives to cosmetic surgeries, and a large number of plastic surgeons offering cosmetic surgery. Rise in per capita income of customers can act as a catalyst for more demand in the market. The demand for facial aesthetic services and anti-aging treatments can fuel the market growth. According to the International Society of Aesthetic Plastic Surgery in 2018, the large number of non-cosmetic surgical procedures reached 3,729,833 globally.
Get a FREE Sample (Including COVID19 Impact Analysis, Full TOC, Tables and Figures) of Dermal Fillers Market @ https://www.marketresearchfuture.com/sample_request/3893 
The outbreak of the COVID-19 pandemic has led to a sharp decline in demand and revenue and it is touted to recover by 2022. According to a report by Hamilton Fraser in conjunction with the National Health Service, an agency in the U.K. government, close to 80% of the clinics were closed during the lockdown bringing down revenue inflow.
Adverse effects of dermal fillers and the alarming numbers of unregistered surgeons performing cosmetic surgery can threaten market growth.
Covid-19 Impact Analysis of the Global Dermal Fillers Market
Dermal fillers are widely used in minimally invasive procedures as an anti-aging solution to reduce facial lines and restore facial firmness. Dermal fillers are used to enhance shallow contours, remove wrinkles, soften facial creases, and improve the appearance of scars using different types of products. Increasing awareness about the benefits of dermal fillers, in comparison to surgical procedures, is leading to its widespread acceptance among the population of all age groups.
Coronavirus pandemic is affecting the global dermal fillers market. The emergence of novel coronavirus disease (COVID-19) in 2020. As of now it has affected more than 4 million people across the globe and caused as many as 281,736 deaths. Major markets for dermal fillers such as the US, China, Spain, Italy, Germany, France, and the UK are suffering huge economic loss due to the disease. Many companies are sacking employees to sustain in the market. It is expected to increase unemployment, resulting in reducing the purchasing power of customers. Thus, people will be more selective about beauty and cosmetic procedures due to decreased purchasing power because of personal and financial losses. It is anticipated to restrict the growth of the market during the forecast period.
Market Research Future (MRFR) collected data on several factors including implications of COVID 19 Impact on Dermal Fillers Market and demographic challenges, showed how it could move forward in the coming years.
Dermal Fillers Market Segmentation
The global dermal fillers market is segmented by type, brand, and application.
By type, the market has been segmented into collagen, calcium hydroxylapatite, hyaluronic acid, and polymers & particles. By type hyaluronic acid held the largest market value of USD 1,154.96 million in 2018 and is expected to grow at the highest CAGR during the forecasted year.
Based on brand, the market has been segmented into radiesse, juvederm, and restylane.
On the basis of application, the market has been segmented into face-lift, facial line correction treatment, and lip treatments.
Dermal Fillers Market Regional Analysis
Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) are regions taken into consideration with respect to the global dermal filler market.
The Americas held the largest market share in 2018. The regional market can showcase growth owing to the demand for cosmetic products, launch of minimally invasive procedures, clinical trials for new skin care products, and a large geriatric populace. According to the annual plastic surgery procedure statistics, there were close to 17.5 million surgical procedures performed in the U.S. in 2017.
Europe will follow the Americas in the market and be the second-best performing region during the assessment period. Acceptance of aesthetic products, support by government bodies for the use of minimally invasive procedures, and a large number of approvals by federal regulatory bodies.
APAC is expected to display the highest growth rate in the global dermal fillers market due to awareness of non-invasive cosmetic procedures, demand for facial aesthetics, and a large geriatric population. According to the United Nations Population Fund (UNFPA), there would be close to 1.3 billion people in the region above the age of 60.
Lastly, the MEA region can display the lowest growth rate during the forecast period due to limited access to cosmetic treatments. But the emergence of beauty clinics and dedicated units to cosmetics in hospitals in Saudi Arabia can drive the regional market growth.
Dermal Fillers Market Competition Outlook
Dr. Korman Laboratories, Medytox, Galderma Laboratories, LP, Allergan, Sinclair Pharma, Merz Pharma, Suneva Medical, Teoxane Laboratories, SciVision Biotech Inc., and others are key players of the global dermal filler market.
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/dermal-fillers-market-3893

 

Posted by at No comments:
Subscribe to: Posts (Atom)